MAIA Biotechnology, Inc. (NYSEAM: MAIA)
Health Care · Biotechnology · US
$1.35
-2.88% today · -12.0% 1Y
MAIA Biotechnology, Inc. (NYSEAM: MAIA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $84.55M and employs 13 people.
Over the last twelve months the share price has lost 12.0%, trading between 0.87 and 3.19.
Tweenvest scores MAIA Biotechnology, Inc. across four factors: quality 25/100. Its strongest factor is quality.
MAIA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $84.55M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.61
- Dividend yield
- —
- Beta (5Y)
- 0.25
- 52-week high
- $3.19
- 52-week low
- $0.87
- Avg volume (3M)
- —
- Shares outstanding
- 60.83M
- Employees
- 13
- Next earnings
- —
About MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
- ISIN
- US5526411021
- Founded
- 2018
- Listed since
- Jul 28, 2022
- Exchange
- NYSE American LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $138.89 | -4.26% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.